- Home
- DRCT vs ESLA Comparison
DRCT vs ESLA Comparison
Compare DRCT & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- ESLA
- Stock Information
- Founded
- DRCT 2018
- ESLA 2021
- Country
- DRCT United States
- ESLA United States
- Employees
- DRCT N/A
- ESLA N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DRCT Technology
- ESLA Health Care
- Exchange
- DRCT Nasdaq
- ESLA Nasdaq
- Market Cap
- DRCT 38.7M
- ESLA 41.6M
- IPO Year
- DRCT 2022
- ESLA N/A
- Fundamental
- Price
- DRCT $1.29
- ESLA $1.18
- Analyst Decision
- DRCT Strong Buy
- ESLA
- Analyst Count
- DRCT 3
- ESLA 0
- Target Price
- DRCT $21.00
- ESLA N/A
- AVG Volume (30 Days)
- DRCT 7.7M
- ESLA 17.0K
- Earning Date
- DRCT 11-12-2024
- ESLA 02-12-2025
- Dividend Yield
- DRCT N/A
- ESLA N/A
- EPS Growth
- DRCT N/A
- ESLA N/A
- EPS
- DRCT N/A
- ESLA N/A
- Revenue
- DRCT $94,216,000.00
- ESLA N/A
- Revenue This Year
- DRCT N/A
- ESLA N/A
- Revenue Next Year
- DRCT $37.23
- ESLA N/A
- P/E Ratio
- DRCT N/A
- ESLA N/A
- Revenue Growth
- DRCT N/A
- ESLA N/A
- 52 Week Low
- DRCT $0.51
- ESLA $0.63
- 52 Week High
- DRCT $35.88
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- DRCT 46.10
- ESLA 51.64
- Support Level
- DRCT $1.10
- ESLA $1.05
- Resistance Level
- DRCT $2.61
- ESLA $1.27
- Average True Range (ATR)
- DRCT 0.50
- ESLA 0.15
- MACD
- DRCT -0.07
- ESLA -0.01
- Stochastic Oscillator
- DRCT 8.64
- ESLA 53.33
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.